• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
All
Options & Futures
Funds
IPO Subscription
Structured Products
Investment Wiki
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov27
Ardelyx Reports 22% Q3 Revenue Growth and Raises Full-Year IBSRELA Sales Guidance
22:51
Nov7
Ardelyx Inc. Presents New Evidentiary Studies on Tenapanor
21:05
Oct31
Ardelyx Inc. Reports Strong Revenue Growth for Flagship Drug Ibsrela
11:54
Oct30
Ardelyx released FY2025 Q3 earnings on October 30 After-Market EST, actual revenue USD 110.33 M (forecast USD 100.54 M), actual EPS USD -0.004 (forecast USD -0.0627)
23:00
Ardelyx released FY2025 9 Months Earnings on October 30 After-Market EST, actual revenue USD 282.11 M, actual EPS USD -0.2559
23:00
Oct28
Ardelyx Inc. Showcases Clinical Data for IBSRELA®
12:03

Schedules & Filings

Schedules
Filings
Oct30
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 110.33 M, Net Income -969 K, EPS -0.004

Aug4
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 97.66 M, Net Income -19.08 M, EPS -0.0795

May1
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 74.11 M, Net Income -41.14 M, EPS -0.1724

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
EKSO
10.580
+93.77%
+5.120
AEHL
2.180
+92.92%
+1.050
AFJK
82.580
+89.19%
+38.930
PFSA
0.1218
+78.33%
+0.053
DLXY
1.410
+67.86%
+0.570
ULY
2.760
+52.49%
+0.950
MENS
4.220
+51.80%
+1.440
CETX
2.980
+41.23%
+0.870
DAIC
0.5500
+39.06%
+0.154
ONTF
8.060
+37.54%
+2.200
View More